Advertisement

Indian Pediatrics

, Volume 55, Issue 12, pp 1066–1074 | Cite as

Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP) Recommended Immunization Schedule (2018-19) and Update on Immunization for Children Aged 0 Through 18 Years

  • S Balasubramanian
  • Abhay Shah
  • Harish K PemdeEmail author
  • Pallab Chatterjee
  • S Shivananda
  • Vijay Kumar Guduru
  • Santosh Soans
  • Digant Shastri
  • Remesh Kumar
Recommendations
  • 9 Downloads

Abstract

Justification

There is a need to revise/review recommendations regarding existing vaccines in view of current developments in vaccinology.

Process

Advisory Committee on Vaccines and Immunization Practices (ACVIP) of Indian Academy of Pediatrics (IAP) reviewed the new evidence, had two meetings, and representatives of few vaccine manufacturers also presented their data. The recommendations were finalized unanimously.

Objectives

To revise and review the IAP recommendations for 2018–19 and issue recommendations on existing and certain new vaccines.

Recommendations

The major changes in the IAP 2018–19 Immunization Timetable include administration of hepatitis B vaccine within 24 hours of age, acceptance of four doses of hepatitis B vaccine if a combination pentavalent or hexavalent vaccine is used, administration of DTwP or DTaP in the primary series, and complete replacement of oral polio vaccine (OPV) by injectable polio vaccine (IPV) as early as possible. In case IPV is not available or feasible, the child should be offered three doses of bivalent OPV. In such cases, the child should be advised to receive two fractional doses of IPV at a Government facility at 6 and 14 weeks or at least one dose of intramuscular IPV, either standalone or as a combination, at 14 weeks. The first dose of monovalent Rotavirus vaccine (RV1) can be administered at 6 weeks and the second at 10 weeks of age in a two-dose schedule. Any of the available rotavirus vaccine may be administered. Inactivated influenza vaccine (either trivalent or quadrivalent) is recommended annually to all children between 6 months to 5 years of age. Measles-containing vaccine (MMR/MR) should be administered after 9 months of age. Additional dose of MR vaccine may be administered during MR campaign for children 9 months to 15 years, irrespective of previous vaccination status. Single dose of Typhoid conjugate vaccine (TCV) is recommended from the age of 6 months and beyond, and can be administered with MMR vaccine if administered at 9 months. Four-dose schedule of anti-rabies vaccine for Post Exposure Prophylaxis as recommended by World Health Organization in 2018, is endorsed, and monoclonal rabies antibody can be administered as an alternative to Rabies immunoglobulin for post-exposure prophylaxis.

Keywords

Guidelines Immunity Infections Prevention Vaccination 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vashishtha VM, Choudhury P, Kalra A, Bose A, Thacker N, Yewale VN, et al. Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years–India, 2014 and updates on immunization. Indian Pediatr. 2014;51:785–800.CrossRefGoogle Scholar
  2. 2.
    Hepatitis B vaccines: WHO position paper–No 27, 2017, World Health Organization. Weekly epidemiological record. No 27, 2017, 92, 369–392.Google Scholar
  3. 3.
    Elizabeth D. Barnett, Give first dose of HepB vaccine within 24 hours of birth: American Academy of Pediatrics August 28, 2017. Available from: http://www.aappublications.org/news/2017/08/28/HepB082817. Accessed Nov 6, 2018.Google Scholar
  4. 4.
    Cherry JD. Pertussis and Immunizations: Facts, Myths, and Misconceptions. Available from: http://aap–ca.org/pertussis–and–immunizations–facts–myths–andmisconceptions. Accessed November 6, 2018.Google Scholar
  5. 5.
    Munoz FM. Safer pertussis vaccines for children: Trading efficacy for safety. Pediatrics. 2018;142:e20181036.CrossRefGoogle Scholar
  6. 6.
    Jackson DW, Rohani P. Perplexities of pertussis: Recent global epidemiological trends and their potential causes. Epidemiol Infect. 2013;16:1–13.Google Scholar
  7. 7.
    Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J, et al. California pertussis epidemic, 2010. J Pediatr. 2012;161:1091–6.CrossRefGoogle Scholar
  8. 8.
    Centers for Disease Control and Prevention (CDC). Pertussis epidemic—Washington, 2012. Morb Mortal Wkly Rep. 2012;61:517–22.Google Scholar
  9. 9.
    Pertussis vaccines: WHO Position Paper–August 2015 No. 35. World Health Organization. Weekly Epidemiological Record. 2015;90:433–60.Google Scholar
  10. 10.
    World Health Organization. Pertussis Vaccine Evidence to Recommendations (WHO). Available from: http://www.who.int/immunization/position_papers/Pertussis GradeTable3.pdf. Accessed November 6, 2018.Google Scholar
  11. 11.
    WHO Position paper on Pertusis Vaccine, 2005. World Health Organization. Weekly Epidemiological Record. 2005;4:29–40.Google Scholar
  12. 12.
    Schmitt HJ, von König CH, Neiss A, Bogaerts H, Bock HL, Schulte–Wissermann H, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996;275:37–41.CrossRefGoogle Scholar
  13. 13.
    Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine. 2003;21:2003–14.CrossRefGoogle Scholar
  14. 14.
    Carlsson R, Trollfors B. Control of pertussis–lessons learnt from a 10–year surveillance programme in Sweden. Vaccine. 2009;27:5709–18.CrossRefGoogle Scholar
  15. 15.
    Okada K, Ohashi Y, Matsuo F, Uno S, Soh M, Nishima S. Effectiveness of an acellular pertussis vaccine in Japanese children during a non–epidemic period: a matched casecontrol study. Epidem Infection. 2009:137:124–30.Google Scholar
  16. 16.
    World Health Organization. WHO SAGE Pertussis Working Group. Background Paper. SAGE April 2014. Available from: http://www.who.int/immunization/sage/meetings/2014/april/1_Pertussis_background_FINAL4_web.pdf? ua=. Accessed November 15, 2018.Google Scholar
  17. 17.
    World Health Organization. Use of Fractional Dose IPV in Routine Immunization Programmes: Considerations for Decision–making. Available from: http://www.who. int/immunization/diseases/poliomyelitis/endgame_objective2/inactivated_polio_vaccine/fIPV_considerations_for_decision–making_April2017.pdf?ua=1. Accessed November 6, 2018.Google Scholar
  18. 18.
    Vasishtha VM, Choudhary J, Yadav S, Unni JC, Jog P, Kamath SS, et al. Introduction of inactivated poliovirus vaccine in National Immunization Program and polio endgame strategy. Indian Pediatr. 2016;53(Suppl.1):S65–9.Google Scholar
  19. 19.
    Bahl S, Verma H, Bhatnagar P, Haldar P, Satapathy A, Arun Kumar KN, et al. Fractional–dose inactivated poliovirus vaccine immunization campaign — Telangana State, India, June 2016. MMWR. 2016;65:859–63.Google Scholar
  20. 20.
    Resik S, Tejeda A, Mach O, Fonseca M, Diaz M, Alemany N, et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: A randomized controlled trial in Cuba. Vaccine. 2015;33:307–13.CrossRefGoogle Scholar
  21. 21.
    Clarke E, Saidu Y, Adetifa JU, Adigweme I, Hydara MB, Bashorun AO, et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measlesrubella combined vaccine and yellow fever vaccine and when given via different administration routes: A phase 4, randomised, non–inferiority trial in The Gambia. Lancet Glob Health. 2016;4:e534–47.CrossRefGoogle Scholar
  22. 22.
    Troy SB, Kouiavskaia D, Siik J, Kochba E, Beydoun H, Mirochnitchenko O, et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV–infected adults. J Infect Dis. 2015;15:1969–76.CrossRefGoogle Scholar
  23. 23.
    Saleem AF, Mach O, Yousafzai MT, Khan A, Weldon WC, Oberste MS, et al. Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan. Vaccine. 2017;35:3209–14.CrossRefGoogle Scholar
  24. 24.
    Polio vaccines: WHO Position Paper, March 2016. World Health Organization. Weekly Epidemiological Record. 2016;91:145–68.Google Scholar
  25. 25.
    World Health Organization. Detailed Review Paper on Rotavirus Vaccines (presented to the WHO Strategic Advisory Group of Experts (SAGE) on Immunization in April 2009). Geneva, World Health Organization, 2009. Available from: http://www.who.int/immunization/sage/3_Detailed_Review_Paper_on_Rota_Vaccines_17_3_2009.pdf. Accessed November 08, 2018.Google Scholar
  26. 26.
    Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population. Vaccine. 2012;30:4552–7.CrossRefGoogle Scholar
  27. 27.
    Rotavirus vaccines WHO Position Paper–January 2013. Weekly Epidemiological Record. 2013;88:49–64.Google Scholar
  28. 28.
    Rotavirus. In: Hamborsky J, Kroger A, Wolfe S, eds. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine–preventable Diseases. 13th ed. Washington DC: Public Health Foundation, 2015. Available from:https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/rota.pdf. Accessed November 15, 2018.Google Scholar
  29. 29.
    World Health Organization. Rotavirus Report, February 2012. Rotavirus Vaccines Schedules: A Systematic Review of Safety and Efficacy from Randomized Controlled Trials and Observational Studies of Childhood Schedules Using RV1 and RV5 Vaccines. Available from: http://www.who.int/immunization/sage/meetings/2012/april/Soares_K_et_al_SAGE_April_rotavirus.pdf. Accessed November 08, 2018.Google Scholar
  30. 30.
    World Health Organization. Grading of Scientific Evidence–Tables 1–4: Does RV1and RV5 induce protection against rotavirus morbidity and mortality in young children both in low and high mortality settings? Available from: http://www.who.int/immunization/position_papers/rotavirus_grad_rv1_rv5_protection. Accessed November 8, 2018.Google Scholar
  31. 31.
    Naik SP, Zade JK, Sabale RN, Pisal SS, Menon R, Bankar SG, et al. Stability of heat stable, live attenuated rotavirus vaccine (ROTASIIL®). Vaccine. 2017;35:2962–9.CrossRefGoogle Scholar
  32. 32.
    World Health Organization. Background Paper on Typhoid Vaccines for SAGE Meeting (October 2017). Available from: http://www.who.int/immunization/sage /meetings/2017/october/1_Typhoid_SAGE_background_paper_Final_v3B.pdf. Accessed November 08, 2018.Google Scholar
  33. 33.
    World Health Organization. Guidelines on The Quality, Safety and Efficacy of Typhoid Conjugate Vaccines, 2013. Available from: http://www.who.int/biologicals/areas/vaccines/TYPHOID_BS2215_doc_v1.14_WEB_VERSION. pdf. Accessed July 12, 2016.Google Scholar
  34. 34.
    Britto C, Pollard AJ, Voysey M, Blohmke CJ. An appraisal of the clinical features of pediatric enteric fever: Systematic review and meta–analysis of the age–stratified disease occurrence. Clin Infect Dis. 2017;64:1604–11.CrossRefGoogle Scholar
  35. 35.
    World Health Organization. Background Paper to SAGE on Typhoid Policy Recommendations. 2017. Available from: http://www.who.int/immunization/sage/meetings/2017/october/1_Typhoid_SAGE_background_paper_Final_v3B. pdf?ua=1. Accessed November 08, 2018.Google Scholar
  36. 36.
    Typhoid vaccines: WHO Position Paper–March 2018. Weekly Epidemiological Record. 2018;93:153–72.Google Scholar
  37. 37.
    Voysey M, Pollard AJ. Sero–efficacy of Vi–polysaccharide tetanus–toxoid typhoid conjugate vaccine (Typbar–TCV). Clin Infect Dis. 2018;67:18–24.CrossRefGoogle Scholar
  38. 38.
    Vashishtha VM, Yewale VN, Bansal CP, Mehta PJ. Indian Academy of Pediatrics, Advisory Committee on Vaccines and Immunization Practices (ACVIP). IAP perspectives on measles and rubella elimination strategies. Indian Pediatr. 2014;51:719–22.Google Scholar
  39. 39.
    Centers for Disease Control and Prevention. Measles, Mumps, and Rubella (MMR) Vaccination: What Everyone Should Know. Available from: https://www.cdc.gov/vaccines/vpd/mmr/public/index.html. Accessed November 18, 2018.Google Scholar
  40. 40.
    Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: A systematic review and meta–analysis. Lancet. 2011;378:1917–30.CrossRefGoogle Scholar
  41. 41.
    Rudan I, Theodoratou E, Zgaga L, Nair H, Chan KY, Tomlinson M, et al. Setting priorities for development of emerging interventions against childhood pneumonia, meningitis and influenza. J Glob Health. 2012;2:10304.Google Scholar
  42. 42.
    Venkatesh M, Doarn CR, Steinhoff M, Yung J. Assessment of burden of seasonal influenza in India and consideration of vaccination policy. Glob J Med Pub Health. 2016;5:1–10. Available from: http://www.gjmedph.com/uploads/R1–Vo5No5.pdf. Accessed November 18, 2018.Google Scholar
  43. 43.
    Vashishtha VM, Kalra A, Choudhury P. Influenza vaccination in India: Position Paper of Indian Academy of Pediatrics, 2013. Indian Pediatr. 2013;50:867–74.CrossRefGoogle Scholar
  44. 44.
    Hirve S, Krishnan A, Dawood FS, Lele P, Saha S, Rai S, et al. Incidence of influenza–associated hospitalization in rural communities in western and northern India, 2010–2012: A multi–site population–based study. J Infect. 2015;70: 160–70.Google Scholar
  45. 45.
    Chadha MS, Broor S, Gunasekaran P, Potdar VA, Krishnan A, Chawla–Sarkar M, et al. Multisite virological influenza surveillance in India: 2004–2008. Influenza Other Respir Viruses. 2012;6:196–203.CrossRefGoogle Scholar
  46. 46.
    Caini S, Huang QS, Ciblak MA, Kusznierz G, Owen R, Wangchuk S, et al. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study. Influen Other Respir Viruses. 2015;9:3–12.CrossRefGoogle Scholar
  47. 47.
    Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices–United States, 2018–19 Influenza Season. MMWR Recomm Rep. 2018;67:1–20.CrossRefGoogle Scholar
  48. 48.
    World Health Organization. Rabies vaccines: WHO Position Paper, April 2018 Recommendations. Vaccine. 2018;36:5500–3.CrossRefGoogle Scholar
  49. 49.
    Gogtay NJ, Munshi R, Ashwath Narayana DH, Mahendra BJ, Kshirsagar V, Gunale B, et al. Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: A phase 2/3, randomized, single–blind, noninferiority, controlled study. Clin Infect Dis. 2018;66:387–95.CrossRefGoogle Scholar

Copyright information

© Indian Academy of Pediatrics 2018

Authors and Affiliations

  • S Balasubramanian
    • 1
  • Abhay Shah
    • 1
  • Harish K Pemde
    • 1
    • 2
    Email author
  • Pallab Chatterjee
    • 1
  • S Shivananda
    • 1
  • Vijay Kumar Guduru
    • 1
  • Santosh Soans
    • 1
  • Digant Shastri
    • 1
  • Remesh Kumar
    • 1
  1. 1.From Advisory Committee on Vaccines and Immunization Practices (ACVIP)Indian Academy of PediatricsNew DelhiIndia
  2. 2.Department of Pediatrics, Lady Hardinge Medical CollegeKalawati Saran Childern’s HospitalNew DelhiIndia

Personalised recommendations